Uzbekistan Pharmaceutical & Healthcare Industries Overview 2018

Uzbekistan Pharmaceutical & Healthcare Industries Overview 2018

Our new report - "Uzbekistan Pharmaceutical & Healthcare Industries Overview 2018" is released. The report includes Uzbek economic, pharmaceutical and healthcare latest trends in a tailored made systematic and business styled manner. The Overview was developed for decision-makers and industry professionals, life sciences stakeholders globally. It covers the 2012-2017 FY historical data with the forecast of the economics and pharmaceutical market numbers to 2018-2019.


Report name: Pharmaceutical and Healthcare Industries Overview 2018
Country: Uzbekistan
Data years: 2016-2019
Price: EUR 200
How to buy: Buy by Invoice
Contents: Download contents


Uzbekistan Pharmaceutical & Healthcare Industries Overview 2018 provides an essential information about the Uzbek pharmaceutical market, its healthcare landscape, macroeconomic situation and:

  1. The review of country's macroeconomic indicators during 2016-2017, local currency exchange rates dynamics, overall country progress in 2016-2017, and the outlook to 2018;
  2. Uzbek pharmaceutical market sales analysis in 2012-2017;
  3. Major pharmaceutical companies of Uzbekistan as of 2017 results;
  4. Weighted average cost of a pack of pharmaceutical products in Uzbekistan for 2016-2017;
  5. NB! Forecast of total pharmaceutical market sales in Uzbekistan for 2018-2019;
  6. PESTLE impact and SWOT analyses of the local pharmaceutical market in 2017-2018;
  7. Regulatory environment of the pharmaceutical industry of Uzbekistan;
  8. Healthcare system analysis, epidemiology and demographics of Uzbekistan in 2016-2017.


This report will enhance your view of the Uzbek pharmaceutical market, its healthcare environment by making you possible to:

  1. Understand the Uzbek pharmaceutical market from the helicopter point of view;
  2. Develop the marketing plan for your products in Uzbekistan;
  3. Assess the market and revenues opportunities in the Uzbek pharmaceutical market;
  4. Elaborate and initiate the market access process of the pharmaceutical product in Uzbekistan.


(Report Excerpts)

This article is based on the "Uzbekistan Pharmaceutical and Healthcare Industries Overview 2018" report prepared by UPharma Consulting and contains short excerpts from this report.

In recent years, Uzbekistan has enjoyed a strong economic performance on the back of a favorable external environment and improvements in macroeconomic policies. Today Uzbekistan actively develops international trading. The country has own regulations that impact operations.

The country has experienced a trade surplus in recent years. Major exportable items of the country are gold, cotton, manufactures, and textiles. The main export partners of the country are South Korea, Turkey, Japan, US, and Russia. Metal, chemicals, and foodstuffs are the important importable items of the country. For imports, Uzbekistan depends upon countries such as Germany, South Korea, US, and Kazakhstan. Uzbekistan is seeking a rapprochement with the West. Thus, the country has refused to join the Eurasian Economic Union, which was established in 2014.

According to estimates the Uzbek GDP grew 5.3% y-o-y in 2017, from 7% y-o-y in 1H2017 and 7.8% y-o-y in 2016. On the demand side, the main driver of economic growth was investment, including a large public investment program to support real sector development in 2015–19 as well as private and state-owned enterprise investments. However, real investment growth slowed to 8.3% y-o-y in 1H2017 from 11.8% y-o-y in 1H2016. In 2017 81% of the GDP was related to non-state sector of the economy.


Pharmaceutical market of Uzbekistan is the third biggest pharmaceutical market in the CIS after Russia and Ukraine. With growth dynamics of about 8-10%, Uzbek pharmaceutical market is among the fastest-growing markets in the CIS region. The pharmaceutical industry started developing in Uzbekistan in 1993 with the establishing of state-owned Concern Uzpharmsanoat, uniting Uzhimpharm plant and Vaccine scientific and production association.

Development of the proper legislative framework and provision of tax preferences and privileges allowed creating a favorable condition for investments and development of the pharmaceutical industry. The number of pharma companies grew from 2 in 1994 to 68 in 2002 and 130 in 2012.

The new stimulus was given to the industry in 2017 when drug producers were freed from paying all taxes for 5 years. Also, companies, which implement projects for the creation of new production facilities and reconstruction of the existing ones have been granted an exemption from payment of all customs duties when importing technological equipment. The same year, the President of Uzbekistan issued the Order on the establishment of seven free economic zones, which will specialize in the cultivation of medicinal plant materials and their processing in special natural conditions.

Download contents (3 Mb)

About publications

Pharmaceutical & Healthcare Industries Overview 2017/2018 - is a professional industry report, which covers crucial economic, pharmaceutical and healthcare information for decision makers and industry professionals globally. The Overview will be useful for top-managers, business owners, consultants and other stakeholders of the Life Sciences industry, who analyze, plan entering or investing into the one of the CIS pharma markets.

For additional information, please, contact, Eugene Brovko via email or phone +380 (98) 224-98-64

Our new Reports

Будем на связи

"АПфарма Консалтинг"
пр-т. Голосеевский, 30Б
офис 58
Киев, 03039

Телефон: + 380 (97) 953 68 14